Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

• Published in: Nature microbiology Vol. 7; no. 8; pp. 1252 - 1258
• Main Authors: Uraki, Ryuta, Kiso, Maki, Imai, Masaki, Yamayoshi, Seiya, Ito, Mutsumi, Fujisaki, Seiichiro, Takashita, Emi, Ujie, Michiko, Furusawa, Yuri, Yasuhara, Atsuhiro, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Watanabe, Shinji, Hasegawa, Hideki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2022; Nature Publishing Group
• Subjects: 631/326/596/1296; 631/326/596/4130; 64; 82/1; Antiviral agents; Biomedical and Life Sciences; Coronaviruses; DNA-directed RNA polymerase; Immune response; Infectious Diseases; Life Sciences; Medical Microbiology; Microbiology; Monoclonal antibodies; Parasitology; Proteinase inhibitors; Replication; RNA polymerase; RNA-directed RNA polymerase; Rodents; Severe acute respiratory syndrome coronavirus 2; Spike protein; Virology

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian h...